1. Home
  2. SYM vs COGT Comparison

SYM vs COGT Comparison

Compare SYM & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Symbotic Inc.

SYM

Symbotic Inc.

SELL

Current Price

$34.25

Market Cap

5.3B

Sector

Industrials

ML Signal

SELL

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

SELL

Current Price

$27.37

Market Cap

5.5B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SYM
COGT
Founded
2005
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
5.5B
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
SYM
COGT
Price
$34.25
$27.37
Analyst Decision
Buy
Strong Buy
Analyst Count
19
12
Target Price
★ $59.84
$55.82
AVG Volume (30 Days)
1.6M
★ 2.0M
Earning Date
11-23-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.12
N/A
Revenue
★ $2,246,922,000.00
$7,871,000.00
Revenue This Year
$24.54
N/A
Revenue Next Year
$28.88
$5,819.52
P/E Ratio
$292.54
★ N/A
Revenue Growth
★ 25.65
N/A
52 Week Low
$33.17
$27.74
52 Week High
$87.88
$43.73

Technical Indicators

Market Signals
Indicator
SYM
COGT
Relative Strength Index (RSI) 34.83 37.79
Support Level $33.17 N/A
Resistance Level $44.66 $37.34
Average True Range (ATR) 2.09 1.81
MACD -0.19 -0.30
Stochastic Oscillator 16.36 4.41

Price Performance

Historical Comparison
SYM
COGT

About SYM Symbotic Inc.

Symbotic Inc. is an automation technology company that develops solutions to improve operating efficiencies in modern warehouses. The group designs, commercializes, and deploys end-to-end technology systems that significantly enhance supply chain operations. The company automates the processing of pallets, cases, and individual items within warehouse environments. Its systems strengthen operations at the front end of the supply chain and provide benefits to all supply partners downstream. The company operates in two geographical regions: the United States and international markets, with the majority of its revenue generated in the United States.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: